E
Eileen M. O'Reilly
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 533
Citations - 23497
Eileen M. O'Reilly is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 67, co-authored 440 publications receiving 16919 citations. Previous affiliations of Eileen M. O'Reilly include St. Vincent's Health System & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan,Pascal Hammel,Michele Reni,Eric Van Cutsem,Teresa Macarulla,Michael J. Hall,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do Youn Oh,Anke Reinacher-Schick,Giampaolo Tortora,Giampaolo Tortora,Hana Algül,Eileen M. O'Reilly,David McGuinness,Karen Y. Cui,Katia Schlienger,Gershon Y. Locker,Hedy L. Kindler +19 more
TL;DR: Among patients with a germline BRCA mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo, and there was no significant between-group difference in health-related quality of life.
Journal ArticleDOI
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler,Donna Niedzwiecki,Donna Hollis,Susan Sutherland,Deborah Schrag,Herbert Hurwitz,Federico Innocenti,Mary F. Mulcahy,Eileen M. O'Reilly,Timothy F. Wozniak,Joel Picus,Pankaj Bhargava,Robert J. Mayer,Richard L. Schilsky,Richard M. Goldberg +14 more
TL;DR: The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients, and the only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension and proteinuria.
Journal ArticleDOI
Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology
Margaret A. Tempero,Mokenge P. Malafa,Mahmoud M. Al-Hawary,Horacio J. Asbun,Andrew Bain,Stephen W. Behrman,Al B. Benson,Ellen F. Binder,Dana Backlund Cardin,Charles Cha,E. Gabriela Chiorean,Vincent Chung,Brian G. Czito,Mary Dillhoff,Efrat Dotan,Cristina R. Ferrone,Jeffrey M. Hardacre,William G. Hawkins,Joseph M. Herman,Andrew H. Ko,Srinadh Komanduri,Albert C. Koong,Noelle K. LoConte,Andrew M. Lowy,Cassadie Moravek,Eric K. Nakakura,Eileen M. O'Reilly,Jorge Obando,Sushanth Reddy,Courtney L. Scaife,Sarah P. Thayer,Colin D. Weekes,Robert A. Wolff,Brian M. Wolpin,Jennifer L. Burns,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
Itaru Endo,Mithat Gonen,Adam C. Yopp,Kimberly Moore Dalal,Qin Zhou,David S. Klimstra,Michael I. D’Angelica,Ronald P. DeMatteo,Yuman Fong,Lawrence H. Schwartz,Nancy E. Kemeny,Eileen M. O'Reilly,Ghassan K. Abou-Alfa,Hiroshi Shimada,Leslie H. Blumgart,William R. Jarnagin +15 more
TL;DR: At Memorial Sloan-Kettering Cancer Center, intrahepatic cholangiocarcinoma incidence has increased dramatically in the last 16 years and the recent increase in survival seems largely because of improved nonoperative therapy for unresectable disease.
Journal ArticleDOI
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Alan P. Venook,Donna Niedzwiecki,Heinz-Josef Lenz,Federico Innocenti,Briant Fruth,Jeffrey A. Meyerhardt,Deborah Schrag,Claire Greene,Bert H. O'Neil,James N. Atkins,Scott R. Berry,Blase N. Polite,Eileen M. O'Reilly,Richard M. Goldberg,Howard S. Hochster,Richard L. Schilsky,Monica M. Bertagnolli,Anthony B. El-Khoueiry,Peter Watson,Al B. Benson,Daniel Mulkerin,Robert J. Mayer,Charles D. Blanke +22 more
TL;DR: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment.